Home » Stocks » BGNE

BeiGene Ltd. (BGNE)

Stock Price: $334.90 USD 2.43 (0.73%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $334.55 -0.35 (-0.11%) Feb 24, 7:06 PM
Market Cap 30.97B
Revenue (ttm) 265.67M
Net Income (ttm) -1.51B
Shares Out 1.15B
EPS (ttm) -19.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $334.90
Previous Close $332.47
Change ($) 2.43
Change (%) 0.73%
Day's Open 326.68
Day's Range 322.25 - 339.89
Day's Volume 215,467
52-Week Range 118.55 - 388.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

BOSTON & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop No...

Benzinga - 1 week ago

The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application seeking approval for BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenströ...

Business Wire - 1 week ago

CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström's Macr...

Seeking Alpha - 3 weeks ago

Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices

Other stocks mentioned: NVS
Business Wire - 4 weeks ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma

Business Wire - 4 weeks ago

HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License...

Seeking Alpha - 1 month ago

BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. Inmagene in-licensed global rights to four novel pre-clin...

Other stocks mentioned: NVS
Zacks Investment Research - 1 month ago

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

Investors Business Daily - 1 month ago

Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.

Business Wire - 1 month ago

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's anti-PD-1 antibody received approval in China in first-line advanced squamous non-small cell lung cancer.

Zacks Investment Research - 1 month ago

Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.

Other stocks mentioned: NVS
Benzinga - 1 month ago

BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tisleliz...

Other stocks mentioned: AMRX, TTOO
Investors Business Daily - 1 month ago

Beigene stock jumped Tuesday on a cancer drug development deal with Novartis worth up to $2.2 billion, as Vir Biotechnology also announced a hepatitis B tie-up with Gilead Sciences. The post B...

Other stocks mentioned: NVS
Business Wire - 1 month ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Novartis enter into a collaboration to develop, manufacture and commercialize tislelizumab, BeiGene's anti-PD-1 antibody.

Business Wire - 1 month ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Strand Therapeutics and BeiGene entered an option and license agreement aimed at developing, commercializing Strand's mRNA treatmen...

Business Wire - 1 month ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing in...

Business Wire - 1 month ago

BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List (NRDL).

GlobeNewsWire - 2 months ago

Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma

Business Wire - 2 months ago

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces that BLINCYTO® (blinatumomab) for injection has been approved in China in relapsed/refractory B-cell precursor ALL.

Business Wire - 2 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene announces clinical data on BTK inhibitor BRUKINSA (zanubrutinib) in B-cell malignancies and Waldenström's at the 62nd ASH ...

Business Wire - 2 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene presents data on BTK inhibitor BRUKINSA in marginal zone lymphoma and chronic lymphocytic leukemia at the 62nd ASH Annual ...

Business Wire - 2 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innov...

Business Wire - 2 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innov...

Business Wire - 3 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing in...

Seeking Alpha - 3 months ago

BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (S...

Business Wire - 3 months ago

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA® (denosumab) in China.

GuruFocus - 3 months ago

Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and ...

Other stocks mentioned: HCM
Business Wire - 3 months ago

CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung cancer met the primary endpoint at interim...

Seeking Alpha - 3 months ago

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic De...

Other stocks mentioned: BNTX, CALT, IMAB, MRK, PFE, TMO
Business Wire - 3 months ago

HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics Licens...

Business Wire - 3 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene reports recent business highlights, anticipated upcoming milestones and financial results for the third quarter and first n...

Business Wire - 3 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH--BeiGene announces data on BRUKINSA® (zanubrutinib) and tislelizumab to be presented at the 62nd ASH Annual Meeting.

Business Wire - 4 months ago

SAN DIEGO & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla's investigat...

Zacks Investment Research - 4 months ago

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 4 months ago

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

Other stocks mentioned: EBS, HZNP, RGEN
Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor in BeiGene.

The Motley Fool - 4 months ago

Want to invest in an industry that consistently outperforms the S&P 500? Here are three stocks to consider.

Other stocks mentioned: ALXN, BNTX
Business Wire - 5 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents Phase 3 data of tislelizumab in non-squamous non-small cell lung cancer and Phase 2 data of pamiparib in ovarian c...

Business Wire - 5 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thurs, Sept 17...

Business Wire - 5 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Health Canada accepted BeiGene's New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s macroglobulinemia (WM) and grant...

Business Wire - 5 months ago

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion in Shanghai-Hong Kong Stock Connect and inclusion in Hang Seng Composite Index (HSCI).

Seeking Alpha - 5 months ago

BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma

Business Wire - 5 months ago

BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Singlomics enter an exclusive license agreement for Singlomics’ investigational anti-COVID-19 antibodies, includ...

Business Wire - 5 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene appoints Corsee Sanders, Ph.D.

Business Wire - 6 months ago

GUANGZHOU & BEIJING & CAMBRIDGE, Mass--(BUSINESS WIRE)---- $BGNE--Bio-Thera Solutions and BeiGene announce license, distribution, and supply agreement for Avastin® (bevacizumab) biosimilar BAT...

Zacks Investment Research - 6 months ago

BeiGene, Ltd. (BGNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 6 months ago

BEIJING, China and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the Center fo...

Forbes - 7 months ago

More than 100% stock gain without posting an operating profit - that’s what Autodesk, Alnylam Pharma, BeiGene, Chegg, and Coupa Software have done over the past three years! This counter-intui...

Other stocks mentioned: ADSK, COUP

About BGNE

BeiGene,, a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumo... [Read more...]

Industry
Biotechnology
IPO Date
Feb 3, 2016
CEO
John Oyler
Employees
4,600
Stock Exchange
NASDAQ
Ticker Symbol
BGNE
Full Company Profile

Financial Performance

In 2019, BeiGene's revenue was $428.21 million, an increase of 116.03% compared to the previous year's $198.22 million. Losses were -$948.63 million, 40.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for BeiGene stock is "Buy." The 12-month stock price forecast is 314.02, which is a decrease of -6.23% from the latest price.

Price Target
$314.02
(-6.23% downside)
Analyst Consensus: Buy